[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postpartum-preeclampsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postpartum-preeclampsia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100620878","nifedipine-and-enalapril-vs-nifedipine-and-labetalol-for-the-treatment-of-postpartum-hypertension-study-100620878",false,"NCT07363343","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NEPHRON)","NEPHRON","Inclusion Criteria:\n\n* Postpartum women aged 18 years or older\n* Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features)\n* Taking Nifedipine 60 mg every 12 hours for blood pressure control\n* Persistently elevated blood pressure at\u002Fabove 140\u002F90 mmHg in a 24-hour time period or have one or more severe range blood pressure at\u002Fabove 160\u002F110 mmHg requiring a second antihypertensive medication\n* English speaking\n\nExclusion Criteria:\n\n* Taking ≥2 antihypertensive agents during pregnancy\n* Heart block\n* Heart rate \\\u003C60 or \\>120 beats per minute\n* Heart failure\n* Creatinine \\>1.5 mg\u002FdL\n* Renal artery stenosis\n* Active connective tissue disease\n* Cerebrovascular accident\n* Failed treatment or contraindications to nifedipine, enalapril or labetalol","FEMALE","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.",[27,28],"Hypertension","Postpartum Preeclampsia","RECRUITING","2026-06-11",{"date":32,"type":33},"2026-06-12","ACTUAL",{"date":35,"type":33},"2026-03-10",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"The Cleveland Clinic","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100607180","postpartum-preeclampsia-early-detection-and-treatment-nepal-pilot-study-100607180","NCT07185204","Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study","Postpartum Preeclampsia Early Detection and Treatment: Using Biomarkers to Implement Risk-stratified Intervention (Nepal Pilot Randomized Controlled Trial)","PREDiCT-NPL","Inclusion Criteria:\n\n* Pregnant patients ≥ 36 weeks gestation without major fetal anomalies\n* Age ≥ 18 years\n* Admitted for labor at Dhulikhel Hospital, or intend to deliver at Dhulikhel Hospital\n* At risk for preeclampsia, using the Clinical Risk Assessment for Preeclampsia according to ACOG and USPSTF\n\n  * 1 or more high risk factors:\n\n    * History of preeclampsia\n    * Type 1 or 2 diabetes\n    * Multifetal gestation?\n    * Renal disease\n    * Autoimmune disease\n  * 2 or more moderate risk factors:\n\n    * Nulliparity\n    * BMI \\> 30\n    * First-degree relative with a history of preeclampsia\n    * African American race\n    * Low socioeconomic status\n    * Age \\> 35 years\n    * History of low birthweight or small for gestational age\n    * Previous adverse pregnancy outcome\n    * Interpregnancy interval \\> 10 years\n\nExclusion Criteria:\n\n* Antenatal hypertensive disorder of pregnancy diagnosis, including gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome, according to ACOG guidelines\n* Chronic hypertension, according to ACOG guidelines\n* Known allergy or contraindication to nifedipine\n* Inability or unwillingness to provide informed consent\n* Two or more blood pressures with an SBP ≥140 or DBP ≥90 after consent and prior to sFlt-1\u002FPlGF testing (screen failure criteria)",{"count":51,"type":21},60,[24],"The goal of this study is to address the significant morbidity associated with preeclampsia diagnosed after delivery. All participants will undergo biomarker evaluation with soluble fms-like tyrosine kinase-1 and placental growth factor (sFlt-1\u002FPlGF) ratio testing before delivery to assess the predictive ability of these biomarkers with new-onset postpartum preeclampsia. High-risk participants will be randomized to a bundle of care strategies aimed at early detection and management of postpartum preeclampsia.",[28],[56,27,57,58],"Preeclampsia","Pregnancy","Postpartum","NOT_YET_RECRUITING","2026-03-12",{"date":62,"type":33},"2026-03-13",{"date":64,"type":21},"2026-05",{"date":66,"type":21},"2027-05",{"name":68,"class":40},"Medical College of Wisconsin",2,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100580866","rhode-island---statewide-postpartum-hypertension-remote-surveillance-100580866","NCT06842875","Rhode Island - Statewide Postpartum Hypertension Remote Surveillance","Effect of a Technology-based Collaborative Model on Persistent Hypertension and Preventive Care Attendance Among Postpartum People With Hypertensive Disorders of Pregnancy","RI-SPHERES","Inclusion Criteria:\n\n* Postpartum patient aged 18 years or more at any birthing hospital in Rhode Island\n* Diagnosed during pregnancy or after delivery with hypertensive disorder of pregnant\n* English-, Spanish-, Portuguese-, or Haitian-Creole-speaking\n* Smartphone ownership\n\nExclusion Criteria:\n\n* Prior enrollment in this trial\n* Prisoners or incarcerated people\n* Inability or unwillingness to provide informed consent\n* Inability to communicate with study team, despite an interpreter","60 Years",{"count":80,"type":21},1536,[24],"This is a hybrid type 1 non-inferiority implementation effectiveness trial among postpartum patients with hypertension (N=1536) that will test the hypothesis that RI-SPHERES (a technologically enabled collaborative care model) is non-inferior to a standard self-measured blood pressure program in terms of persistent hypertension at six weeks postpartum and preventive care receipt within one year of delivery.",[84,28,85],"Hypertension in Pregnancy","Postpartum Complication",[87,88,89,90,91,92],"postpartum hypertensive disorders of pregnancy","postpartum preeclampsia","digital health","collaborative care model","population health","self-measured blood pressure","2025-06-12",{"date":95,"type":33},"2025-06-17",{"date":97,"type":33},"2025-04-15",{"date":99,"type":21},"2029-03-01",{"name":101,"class":40},"Women and Infants Hospital of Rhode Island",5,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100463036","phase-4-labetalol-or-nifedipine-for-control-of-postpartum-hypertension-a-randomized-controlled-trial-100463036","NCT05309460","Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial","Inclusion Criteria:\n\nAny patient admitted for delivery by cesarean or vaginal delivery at 24 weeks gestation or greater with hypertension(HTN). Hypertension will be defined during the study as either a systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg on two occasions at least 4 hours apart. This definition is consistent with the ACOG definition for pregnancy related HTN. Following enrollment, treatment will be escalated at discretion of primary provider with the goal of normotension.\n\nExclusion Criteria:\n\nHistory of moderate persistent asthma, coronary artery disease, heart failure, AV heart block, pulmonary edema\n\n* Contraindication to either Nifedipine or Labetalol\n* HR \\\u003C60 or \\>110\n* Native language other than English or Spanish","19 Years",{"count":111,"type":21},600,[113],"PHASE4","Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.",[28,84],[117,118,58,27,56,57],"Nifedipine","Labetalol","2024-04-10",{"date":121,"type":33},"2024-04-12",{"date":123,"type":33},"2022-06-20",{"date":125,"type":21},"2024-12-01",{"name":127,"class":40},"Nebraska Methodist Health System"]